SG Americas Securities LLC Boosts Holdings in AxoGen, Inc. (NASDAQ:AXGN)

SG Americas Securities LLC increased its position in shares of AxoGen, Inc. (NASDAQ:AXGN) by 45.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 14,823 shares of the medical equipment provider’s stock after buying an additional 4,666 shares during the quarter. SG Americas Securities LLC’s holdings in AxoGen were worth $101,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Envestnet Asset Management Inc. raised its position in AxoGen by 2.8% in the second quarter. Envestnet Asset Management Inc. now owns 42,906 shares of the medical equipment provider’s stock valued at $351,000 after purchasing an additional 1,187 shares during the period. Rhumbline Advisers increased its position in shares of AxoGen by 2.9% during the 2nd quarter. Rhumbline Advisers now owns 54,379 shares of the medical equipment provider’s stock worth $496,000 after purchasing an additional 1,527 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in AxoGen by 7.2% in the 4th quarter. JPMorgan Chase & Co. now owns 23,912 shares of the medical equipment provider’s stock valued at $238,000 after buying an additional 1,612 shares during the period. Charles Schwab Investment Management Inc. lifted its position in AxoGen by 0.7% in the first quarter. Charles Schwab Investment Management Inc. now owns 296,989 shares of the medical equipment provider’s stock valued at $2,359,000 after buying an additional 2,193 shares during the last quarter. Finally, Almanack Investment Partners LLC. purchased a new position in AxoGen during the third quarter worth about $27,000. 80.29% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at AxoGen

In related news, CEO Karen L. Zaderej sold 39,280 shares of AxoGen stock in a transaction on Thursday, March 21st. The stock was sold at an average price of $7.68, for a total value of $301,670.40. Following the completion of the transaction, the chief executive officer now directly owns 1,124,565 shares in the company, valued at $8,636,659.20. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other AxoGen news, VP Michael Patrick Donovan sold 36,310 shares of the stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $8.81, for a total value of $319,891.10. Following the sale, the vice president now directly owns 35,708 shares of the company’s stock, valued at approximately $314,587.48. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Karen L. Zaderej sold 39,280 shares of AxoGen stock in a transaction on Thursday, March 21st. The stock was sold at an average price of $7.68, for a total transaction of $301,670.40. Following the sale, the chief executive officer now directly owns 1,124,565 shares of the company’s stock, valued at $8,636,659.20. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 111,201 shares of company stock valued at $928,054. 7.21% of the stock is currently owned by company insiders.

AxoGen Stock Down 0.8 %

Shares of AXGN opened at $6.50 on Friday. The company’s 50-day simple moving average is $8.61 and its 200-day simple moving average is $7.29. The company has a debt-to-equity ratio of 0.71, a quick ratio of 2.14 and a current ratio of 2.89. AxoGen, Inc. has a 1 year low of $3.45 and a 1 year high of $10.83. The stock has a market capitalization of $283.97 million, a PE ratio of -12.50 and a beta of 1.03.

AxoGen (NASDAQ:AXGN) last released its earnings results on Tuesday, March 5th. The medical equipment provider reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.11. AxoGen had a negative net margin of 13.66% and a negative return on equity of 22.38%. The company had revenue of $42.92 million for the quarter, compared to analyst estimates of $42.70 million. Analysts forecast that AxoGen, Inc. will post -0.46 earnings per share for the current fiscal year.

Analysts Set New Price Targets

AXGN has been the topic of a number of research analyst reports. StockNews.com raised shares of AxoGen from a “hold” rating to a “buy” rating in a research note on Wednesday, February 28th. Cantor Fitzgerald reissued an “overweight” rating and issued a $12.00 target price on shares of AxoGen in a research report on Friday, January 19th.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.